Clinical trial
Phase III Randomized Trial of Thalidomide/Dexamethasone vs VAD as Induction Chemotherapy for Newly Diagnosed Myeloma Patients and Evaluation of the Effects of Zoledronate on Chemotherapy Induced Apoptosis and Antigen Presentation.
NCT00215943 is registered in ClinicalTrials.gov with H. Lee Moffitt Cancer Center and Research Institute as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase III Randomized Trial of Thalidomide/Dexamethasone vs VAD as Induction Chemotherapy for Newly Diagnosed Myeloma Patients and Evaluation of the Effects of Zoledronate on Chemotherapy Induced Apoptosis and Antigen Presentation.
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- June 30, 2003
- Completion date
- August 31, 2012
- Enrollment
- 90 (actual)
- Sites
- 5
Conditions
As the registry lists them; a condition with its own page is linked.